Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
41.17
+0.37 (0.91%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Nektar Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Buy" and an average price target of $133.36. The average 1-year stock price forecast is 223.93% higher than the current stock price, while the lowest is $50 (+21.45%) and the highest is $192 (+366.36%).
Price Target: $133.36 (+223.93%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nektar Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 2 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 12 | 12 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Raymond James No rating | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 8, 2026 |
| Citi | Citi | Buy Reiterates $151 | Buy | Reiterates | $151 | +266.77% | Oct 5, 2026 |
Unknown Analyst B. Riley Securities No rating | B. Riley Securities | Buy Maintains $150 | Buy | Maintains | $150 | +264.34% | Oct 2, 2026 |
| Jefferies | Jefferies | Buy Maintains $150 | Buy | Maintains | $150 | +264.34% | Oct 1, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 1, 2026 |
Financial Forecast
Revenue This Year
41.86M
from 55.23M
Decreased by -24.21%
Revenue Next Year
54.42M
from 41.86M
Increased by 30.00%
EPS This Year
-8.26
from -8.66
EPS Next Year
-10.30
from -8.26
EPS and Forward PE are based on non-GAAP adjusted numbers.